On April 27, the "Sustained Balance, Fulfilling Princess Dreams—The First Hengli Princess Hyaluronic Acid Injection Technology Forum," hosted by China National Pharmaceutical Group Lanzhou Biotechnology Development Co., Ltd., was held at Beijing United Beauty First Medical Aesthetic Hospital under the Lige Group.Attendees included Professor Chen Guangyu from the Injection Aesthetics Center of the Plastic Surgery Hospital, Chinese Academy of Medical Sciences; Chen Cuiyun, Technical Director of Beijing United Lige First Hospital; and Cao Ling, Director of the Non-Invasive Department at Beijing Lido Medical Aesthetics Hospital. Additionally, over 50 medical professionals from institutions across the Beijing-Tianjin region gathered for this beauty-focused event.
Professor Chen Guangyu: Muscle Anatomy Related to Botulinum Toxin and Hyaluronic Acid Injections
Director Chen Cuiyun: How to Achieve Your Princess Look with Princess Hyaluronic Acid
Director Cao Ling: Applications of Princess Hyaluronic Acid in Facial Aesthetics
Professor Cao Yilin, Chairman of United Lige First Medical Aesthetic Hospital, delivered the opening address.Professor Cao Yilin stated that United Beauty First Hospital boasts a dream team of medical aesthetics professionals, aiming to become a private hospital integrating teaching and research in plastic surgery. He expressed hope that this injection exchange forum would provide physicians with more opportunities for academic exchange and contribute to advancing China's injectable aesthetics industry!
Professor Cao Yilin delivers opening remarks for the forum
During the event, organizers introduced product development for Hengli Botulinum Toxin and demonstrated injection techniques. Currently, Hengli Botulinum Toxin is registered and sold in 34 countries and regions including Brazil, South Korea, and Russia.Additionally, presentations covered the application of Austrian Princess hyaluronic acid in facial aesthetic design and targeted injection protocols, complemented by live facial assessments and injection demonstrations.
Hengli originates from Sinopharm China National Biotec Group. It received its New Drug Certificate and trial production approval from the Ministry of Health in 1993, gained market approval in 1997, and has been administered to over 27 million patients to date.In China, Hengli accounts for 8 out of every 10 units of Type A botulinum toxin injected. In 2020, Hengli became the first domestically approved Type A botulinum toxin product for treating upper limb spasticity in adults following stroke. This filled a therapeutic gap in China for upper limb spasticity treatment with Type A botulinum toxin, addressing the challenges faced by millions of patients annually suffering from limb spasticity symptoms.
Last year, Sinopharm China National Biotec Group entered into a long-term cooperation agreement with Croma-Pharma GmbH (hereinafter referred to as Croma), an Austrian medical aesthetics manufacturer specializing in hyaluronic acid product development for nearly 45 years. This partnership secured exclusive distribution rights for Croma's hyaluronic acid injectable product Princess?VOLUME.As a family-owned pharmaceutical enterprise, Croma is globally renowned for its expertise in pre-filled viscoelastics for ophthalmology, plastic surgery, and aesthetic medicine. With an annual production capacity of 6 million vials, it ranks among the world's leading manufacturers of premium injectables.Its hyaluronic acid injectable Princess?VOLUME adheres to stringent international safety standards in production, toxicology, and biocompatibility validation, all certified compliant. Its proprietary and leading MACRO technology ensures high stability and long-lasting effects, making it an ideal companion for refined aesthetic enhancement.
Moving forward, Hengli will continue to focus on applying new clinical medical technologies and methods to cultivate a new aesthetic medicine ecosystem.